Education
About Us
Working with TipRanks
Follow Us
Anebulo Pharmaceuticals (ANEB)
NASDAQ:ANEB
ANEB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.80 - $3.30
Previous CloseN/A
Volume2.65K
Average Volume (3M)39.13K
Market Cap
$41.50M
Enterprise Value$48.65M
Total Cash (Recent Filing)$15.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
May 08, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding41,084,732
10 Day Avg. Volume11,167
30 Day Avg. Volume39,133
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.55
Forecast
1Y Price Target
$8.00Price Target Upside751.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Anebulo Pharmaceuticals News
PremiumCompany Announcements
Anebulo Pharmaceuticals Reports Fiscal Q2 2025 Results
PremiumPre-Earnings
Is ANEB a Buy, Before Earnings?
PremiumCompany Announcements
Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions
PremiumCompany Announcements
Anebulo Pharmaceuticals Updates Corporate Presentation---
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst maintains a Speculative Buy rating on ANEB shares due to the continuing need for a treatment for acute cannabis-induced toxicity and the company’s earlier positive results for its selonabant therapeutic.
Clinical ResultsThe company announced clinical results from a Phase 2 proof-of-concept study with 134 adult subjects using oral selonabant to treat acute cannabis-induced toxicity.
Financial ResourcesAnebulo has adequate financial resources to fund operations well into calendar year 2026.
Bears Say
Equity PlacementAnebulo completed a $15 million equity private placement during the second quarter and held approximately $15.0 million in cash on hand.
Grant DependencyThe company received a $1.9 million grant from the US National Institute on Drug Abuse (NIDA) to support the development of IV selonabant in the emergency treatment of acute cannabis-induced toxicities.
Market FocusAnebulo Pharmaceuticals is focusing on the development of intravenous (IV) selonabant for the treatment of acute cannabis-induced toxic effects, particularly in pediatric cases.
---
Ownership Overview
78.18% Insiders
0.58% Mutual Funds
1.68% Other Institutional Investors
19.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANEB FAQ
What was Anebulo Pharmaceuticals’s price range in the past 12 months?
Anebulo Pharmaceuticals lowest stock price was $0.80 and its highest was $3.30 in the past 12 months.
What is Anebulo Pharmaceuticals’s market cap?
Anebulo Pharmaceuticals’s market cap is $41.50M.
When is Anebulo Pharmaceuticals’s upcoming earnings report date?
Anebulo Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 28 days.
How were Anebulo Pharmaceuticals’s earnings last quarter?
Anebulo Pharmaceuticals released its earnings results on Feb 14, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.01.
Is Anebulo Pharmaceuticals overvalued?
According to Wall Street analysts Anebulo Pharmaceuticals’s price is currently Undervalued.
Does Anebulo Pharmaceuticals pay dividends?
Anebulo Pharmaceuticals does not currently pay dividends.
What is Anebulo Pharmaceuticals’s EPS estimate?
Anebulo Pharmaceuticals’s EPS estimate is -0.05.
How many shares outstanding does Anebulo Pharmaceuticals have?
Anebulo Pharmaceuticals has 41,084,732 shares outstanding.
What happened to Anebulo Pharmaceuticals’s price movement after its last earnings report?
Anebulo Pharmaceuticals reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went up 9.774%.
Which hedge fund is a major shareholder of Anebulo Pharmaceuticals?
Currently, no hedge funds are holding shares in ANEB
---
Anebulo Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (751.06% Upside)
$8.00 (751.06% Upside)
Insider Transactions
Bought Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.74%
12-Months-Change
Fundamentals
Return on Equity
-71.49%
Trailing 12-Months
Asset Growth
111.19%
Trailing 12-Months
Company Description
Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
---
ANEB Stock 12 Month Forecast
Average Price Target
$8.00
▲(751.06% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
vTv Therapeutics
―
Prelude Therapeutics
―
Aligos Therapeutics
―
Hyperfine
―
Best Analysts Covering ANEB
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-26.65%
reiterated a buy rating last month
Copying Robert Wasserman's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -26.65% per trade.
---